BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

486 related articles for article (PubMed ID: 8599935)

  • 1. Constitutive activation of fibroblast growth factor receptor 3 by the transmembrane domain point mutation found in achondroplasia.
    Webster MK; Donoghue DJ
    EMBO J; 1996 Feb; 15(3):520-7. PubMed ID: 8599935
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Graded activation of fibroblast growth factor receptor 3 by mutations causing achondroplasia and thanatophoric dysplasia.
    Naski MC; Wang Q; Xu J; Ornitz DM
    Nat Genet; 1996 Jun; 13(2):233-7. PubMed ID: 8640234
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Skeletal overgrowth and deafness in mice lacking fibroblast growth factor receptor 3.
    Colvin JS; Bohne BA; Harding GW; McEwen DG; Ornitz DM
    Nat Genet; 1996 Apr; 12(4):390-7. PubMed ID: 8630492
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential activation of cysteine-substitution mutants of fibroblast growth factor receptor 3 is determined by cysteine localization.
    Adar R; Monsonego-Ornan E; David P; Yayon A
    J Bone Miner Res; 2002 May; 17(5):860-8. PubMed ID: 12009017
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fibroblast growth factor receptor-3 as a therapeutic target for Achondroplasia--genetic short limbed dwarfism.
    Aviezer D; Golembo M; Yayon A
    Curr Drug Targets; 2003 Jul; 4(5):353-65. PubMed ID: 12816345
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A recurrent mutation in the tyrosine kinase domain of fibroblast growth factor receptor 3 causes hypochondroplasia.
    Bellus GA; McIntosh I; Smith EA; Aylsworth AS; Kaitila I; Horton WA; Greenhaw GA; Hecht JT; Francomano CA
    Nat Genet; 1995 Jul; 10(3):357-9. PubMed ID: 7670477
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Common mutations in the fibroblast growth factor receptor 3 (FGFR 3) gene account for achondroplasia, hypochondroplasia, and thanatophoric dwarfism.
    Bonaventure J; Rousseau F; Legeai-Mallet L; Le Merrer M; Munnich A; Maroteaux P
    Am J Med Genet; 1996 May; 63(1):148-54. PubMed ID: 8723101
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Constitutive receptor activation by Crouzon syndrome mutations in fibroblast growth factor receptor (FGFR)2 and FGFR2/Neu chimeras.
    Galvin BD; Hart KC; Meyer AN; Webster MK; Donoghue DJ
    Proc Natl Acad Sci U S A; 1996 Jul; 93(15):7894-9. PubMed ID: 8755573
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mutations of the fibroblast growth factor receptor-3 gene in achondroplasia.
    Rousseau F; Bonaventure J; Legeai-Mallet L; Pelet A; Rozet JM; Maroteaux P; Le Merrer M; Munnich A
    Horm Res; 1996; 45(1-2):108-10. PubMed ID: 8742128
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chimeras of the native form or achondroplasia mutant (G375C) of human fibroblast growth factor receptor 3 induce ligand-dependent differentiation of PC12 cells.
    Thompson LM; Raffioni S; Wasmuth JJ; Bradshaw RA
    Mol Cell Biol; 1997 Jul; 17(7):4169-77. PubMed ID: 9199352
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The achondroplasia mutation does not alter the dimerization energetics of the fibroblast growth factor receptor 3 transmembrane domain.
    You M; Li E; Hristova K
    Biochemistry; 2006 May; 45(17):5551-6. PubMed ID: 16634636
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [From gene to disease; achondroplasia and other skeletal dysplasias due to an activating mutation in the fibroblast growth factor].
    van Ravenswaaij-Arts CM; Losekoot M
    Ned Tijdschr Geneeskd; 2001 Jun; 145(22):1056-9. PubMed ID: 11414167
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Defective lysosomal targeting of activated fibroblast growth factor receptor 3 in achondroplasia.
    Cho JY; Guo C; Torello M; Lunstrum GP; Iwata T; Deng C; Horton WA
    Proc Natl Acad Sci U S A; 2004 Jan; 101(2):609-14. PubMed ID: 14699054
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transformation and Stat activation by derivatives of FGFR1, FGFR3, and FGFR4.
    Hart KC; Robertson SC; Kanemitsu MY; Meyer AN; Tynan JA; Donoghue DJ
    Oncogene; 2000 Jul; 19(29):3309-20. PubMed ID: 10918587
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predominance of the mutation at 1138 of the cDNA for the fibroblast growth factor receptor 3 in Japanese patients with achondroplasia.
    Tonoki H; Nakae J; Tajima T; Shinohara N; Monji J; Satoh S; Fujieda K
    Jpn J Hum Genet; 1995 Dec; 40(4):347-9. PubMed ID: 8851771
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The transmembrane mutation G380R in fibroblast growth factor receptor 3 uncouples ligand-mediated receptor activation from down-regulation.
    Monsonego-Ornan E; Adar R; Feferman T; Segev O; Yayon A
    Mol Cell Biol; 2000 Jan; 20(2):516-22. PubMed ID: 10611230
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Ser(365)-->Cys mutation of fibroblast growth factor receptor 3 in mouse downregulates Ihh/PTHrP signals and causes severe achondroplasia.
    Chen L; Li C; Qiao W; Xu X; Deng C
    Hum Mol Genet; 2001 Mar; 10(5):457-65. PubMed ID: 11181569
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Lys644Glu substitution in fibroblast growth factor receptor 3 (FGFR3) causes dwarfism in mice by activation of STATs and ink4 cell cycle inhibitors.
    Li C; Chen L; Iwata T; Kitagawa M; Fu XY; Deng CX
    Hum Mol Genet; 1999 Jan; 8(1):35-44. PubMed ID: 9887329
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Constitutive activation of MEK1 in chondrocytes causes Stat1-independent achondroplasia-like dwarfism and rescues the Fgfr3-deficient mouse phenotype.
    Murakami S; Balmes G; McKinney S; Zhang Z; Givol D; de Crombrugghe B
    Genes Dev; 2004 Feb; 18(3):290-305. PubMed ID: 14871928
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Repression of hedgehog signaling and BMP4 expression in growth plate cartilage by fibroblast growth factor receptor 3.
    Naski MC; Colvin JS; Coffin JD; Ornitz DM
    Development; 1998 Dec; 125(24):4977-88. PubMed ID: 9811582
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.